Retour

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Stocks Stock Market News

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.

GlobeNewswire Inc. • 22/04/2024 à 23:06:00
Cidara Therapeutics, Inc.
Address: 6310 NANCY RIDGE DRIVE
Postal Code: 92121
City: SAN DIEGO
State: CA
Phone Number: 858-752-6170
Website: https://www.cidara.com
Status: Active
Company Info

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

List Date2015-04-15
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001610618
Composite figiBBG006R5MFT6
Share Class figiBBG006R5MFV3
Market Cap57,614,915 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees73
Share Class Shares Outstanding4560000
Weighted Shares Outstanding4561751
Round Lot100
Updated date2024-04-28
Stats
Last 5 days
2-05
1-05
30-04
29-04
26-04
Last
11.811
11.655
11.82
12.63
12.81
Variance
1.34%
-1.4%
-6.06%
-1.06%
-1.45%
Open
11.655
11.82
12.583
12.765
12.999
Highest
12.725
11.989
12.591
12.815
13.415
Lowest
12.725
11.82
12.58
12.765
13.415
History
PeriodVarhighestlowest
1 week
-9.14%
13.415
11.82
1 month
1028.08%
1.209
0.575
3 month
1587.29%
0.7
0.575
6 month
1227.08%
0.9081
0.575
1 year
1069.41%
1.03
0.575
3 year
427.28%
2.26
0.4
5 year
418.03%
2.48
0.4
10 year
-26.69%
19.13
0.4
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-03 2023-11-02 UNPUB
Assets 81,736,000 67,986,000 63,468,000 UNPUB
Current Assets 79,488,000 62,240,000 57,704,000 UNPUB
Current Liabilities 35,663,000 31,420,000 35,620,000 UNPUB
Equity 26,837,000 15,414,000 8,038,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 26,837,000 15,414,000 8,038,000 UNPUB
Liabilities 54,899,000 52,572,000 55,430,000 UNPUB
Liabilities And Equity 81,736,000 67,986,000 63,468,000 UNPUB
Noncurrent Assets 2,248,000 5,746,000 5,764,000 UNPUB
Noncurrent Liabilities 19,236,000 21,152,000 19,810,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-03 2023-11-02 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 15,245,000 2,454,000 -1,760,000 UNPUB
Net Cash Flow, Continuing 15,245,000 2,454,000 -1,760,000 UNPUB
Net Cash Flow From Financing Activities 26,237,000 -261,000 0 UNPUB
Net Cash Flow From Financing Activities, Continuing 26,237,000 -261,000 0 UNPUB
Net Cash Flow From Investing Activities -94,000 -107,000 -126,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -94,000 -107,000 -126,000 UNPUB
Net Cash Flow From Operating Activities -10,898,000 2,822,000 -1,634,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -10,898,000 2,822,000 -1,634,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-03 2023-11-02 UNPUB
Comprehensive Income/Loss 3,209,000 -12,357,000 -8,172,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent 3,209,000 -12,357,000 -8,172,000 UNPUB
Other Comprehensive Income/Loss 3,209,000 -12,357,000 -8,172,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-03 2023-11-02 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 22,781,000 19,822,000 20,660,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 23,013,000 20,445,000 20,660,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax 3,209,000 -12,357,000 -8,172,000 UNPUB
Income/Loss From Continuing Operations Before Tax 3,209,000 -12,208,000 -7,942,000 UNPUB
Income Tax Expense/Benefit UNPUB 149,000 230,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss 3,209,000 -12,357,000 -8,172,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent 3,209,000 -12,357,000 -8,172,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic 2,532,000 -12,357,000 -8,172,000 UNPUB
Operating Expenses 23,013,000 20,445,000 21,273,000 UNPUB
Operating Income/Loss 2,977,000 -12,831,000 -8,555,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 677,000 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 677,000 0 0 UNPUB
Revenues 25,990,000 7,614,000 12,718,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 UNPUB 2022-11-03 2023-03-23
Assets 55,295,000 UNPUB 66,858,000 47,593,000
Current Assets 52,007,000 UNPUB 63,899,000 45,094,000
Current Liabilities 32,105,000 UNPUB 33,049,000 29,972,000
Equity 4,957,000 UNPUB 9,067,000 -2,904,000
Equity Attributable To Noncontrolling Interest 0 UNPUB 0 0
Equity Attributable To Parent 4,957,000 UNPUB 9,067,000 -2,904,000
Liabilities 50,338,000 UNPUB 57,791,000 50,497,000
Liabilities And Equity 55,295,000 UNPUB 66,858,000 47,593,000
Noncurrent Assets 3,288,000 UNPUB 2,959,000 2,499,000
Noncurrent Liabilities 0 UNPUB 24,742,000 20,525,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 UNPUB 2022-11-03 2023-03-23
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -24,303,000 UNPUB UNPUB -29,542,000
Net Cash Flow, Continuing -24,303,000 UNPUB UNPUB -29,542,000
Net Cash Flow From Financing Activities -611,000 UNPUB UNPUB -951,000
Net Cash Flow From Financing Activities, Continuing -611,000 UNPUB UNPUB -951,000
Net Cash Flow From Investing Activities -84,000 UNPUB UNPUB -118,000
Net Cash Flow From Investing Activities, Continuing -84,000 UNPUB UNPUB -118,000
Net Cash Flow From Operating Activities -23,608,000 UNPUB UNPUB -28,473,000
Net Cash Flow From Operating Activities, Continuing -23,608,000 UNPUB UNPUB -28,473,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 UNPUB 2022-11-03 2023-03-23
Comprehensive Income/Loss -18,281,000 UNPUB 14,978,000 -29,799,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent -18,281,000 UNPUB 14,978,000 -29,799,000
Other Comprehensive Income/Loss 0 UNPUB 14,978,000 -29,799,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 UNPUB 2022-11-03 2023-03-23
Basic Earnings Per Share 0 UNPUB 0 0
Benefits Costs and Expenses 25,390,000 UNPUB 25,766,000 93,815,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 25,370,000 UNPUB 25,821,000 94,006,000
Diluted Earnings Per Share 0 UNPUB 0 0
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,281,000 UNPUB 14,978,000 -29,799,000
Income/Loss From Continuing Operations Before Tax -18,281,000 UNPUB 14,978,000 -29,527,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 272,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -18,281,000 UNPUB 14,978,000 -29,799,000
Net Income/Loss Attributable To Noncontrolling Interest 0 UNPUB 0 0
Net Income/Loss Attributable To Parent -18,281,000 UNPUB 14,978,000 -29,799,000
Net Income/Loss Available To Common Stockholders, Basic -18,281,000 UNPUB 11,897,000 -29,799,000
Operating Expenses 25,370,000 UNPUB 25,821,000 94,006,000
Operating Income/Loss -18,261,000 UNPUB 14,923,000 -29,718,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 UNPUB 3,081,000 0
Preferred Stock Dividends And Other Adjustments 0 UNPUB 3,081,000 0
Revenues 7,109,000 UNPUB 40,744,000 64,288,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-12 2021-11-10 2022-03-07
Assets 54,210,000 63,744,000 51,206,000 75,325,000
Current Assets 51,301,000 61,076,000 47,276,000 71,698,000
Current Liabilities 39,966,000 33,887,000 33,490,000 34,017,000
Equity 1,892,000 15,789,000 -1,158,000 21,573,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 1,892,000 15,789,000 -1,158,000 21,573,000
Liabilities 52,318,000 47,955,000 52,364,000 53,752,000
Liabilities And Equity 54,210,000 63,744,000 51,206,000 75,325,000
Noncurrent Assets 2,909,000 2,668,000 3,930,000 3,627,000
Noncurrent Liabilities 0 0 18,874,000 19,735,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-12 2021-11-10 2022-03-07
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 5,840,000 4,310,000 -12,794,000 19,324,000
Net Cash Flow, Continuing 5,840,000 4,310,000 -12,794,000 19,324,000
Net Cash Flow From Financing Activities 7,645,000 887,000 -810,000 44,597,000
Net Cash Flow From Financing Activities, Continuing 7,645,000 887,000 -810,000 44,597,000
Net Cash Flow From Investing Activities -12,000 -17,000 -12,000 -41,000
Net Cash Flow From Investing Activities, Continuing -12,000 -17,000 -12,000 -41,000
Net Cash Flow From Operating Activities -1,793,000 3,440,000 -11,972,000 -25,232,000
Net Cash Flow From Operating Activities, Continuing -1,793,000 3,440,000 -11,972,000 -25,232,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-12 2021-11-10 2022-03-07
Comprehensive Income/Loss -18,292,000 10,711,000 -18,083,000 -42,467,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,292,000 10,711,000 -18,083,000 -42,467,000
Other Comprehensive Income/Loss 0 0 -18,083,000 -42,467,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-13 2021-08-12 2021-11-10 2022-03-07
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 20,700,000 22,152,000 25,159,000 92,039,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 20,630,000 22,090,000 25,112,000 91,827,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -18,292,000 10,711,000 -18,083,000 -42,467,000
Income/Loss From Continuing Operations Before Tax -18,292,000 10,711,000 -18,083,000 -42,467,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -18,292,000 10,711,000 -18,083,000 -42,467,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -18,292,000 10,711,000 -18,083,000 -42,467,000
Net Income/Loss Available To Common Stockholders, Basic -18,292,000 8,819,000 -18,083,000 -42,467,000
Operating Expenses 20,630,000 22,090,000 25,112,000 91,827,000
Operating Income/Loss -18,222,000 10,773,000 -18,036,000 -42,255,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 1,892,000 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 2,408,000 32,863,000 7,076,000 49,572,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-13 2020-11-05 2021-02-25
Assets 84,097,000 73,403,000 63,669,000 60,424,000
Current Assets 80,621,000 70,039,000 60,187,000 57,191,000
Current Liabilities 29,629,000 31,567,000 33,871,000 38,564,000
Equity 53,752,000 41,352,000 29,553,000 10,715,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 53,752,000 41,352,000 29,553,000 10,715,000
Liabilities 30,345,000 32,051,000 34,116,000 49,709,000
Liabilities And Equity 84,097,000 73,403,000 63,669,000 60,424,000
Noncurrent Assets 3,476,000 3,364,000 3,482,000 3,233,000
Noncurrent Liabilities 0 0 245,000 11,145,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-13 2020-11-05 2021-02-25
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 14,046,000 -10,229,000 -10,417,000 -17,319,000
Net Cash Flow, Continuing 14,046,000 -10,229,000 -10,417,000 -17,319,000
Net Cash Flow From Financing Activities 29,210,000 3,939,000 3,720,000 37,278,000
Net Cash Flow From Financing Activities, Continuing 29,210,000 3,939,000 3,720,000 37,278,000
Net Cash Flow From Investing Activities -36,000 -96,000 -54,000 -186,000
Net Cash Flow From Investing Activities, Continuing -36,000 -96,000 -54,000 -186,000
Net Cash Flow From Operating Activities -15,128,000 -14,072,000 -14,083,000 -54,411,000
Net Cash Flow From Operating Activities, Continuing -15,128,000 -14,072,000 -14,083,000 -54,411,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-13 2020-11-05 2021-02-25
Comprehensive Income/Loss -14,539,000 -18,306,000 -17,632,000 -72,111,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -14,539,000 -18,306,000 -17,632,000 -72,111,000
Other Comprehensive Income/Loss 0 0 0 -72,111,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-13 2020-08-13 2020-11-05 2021-02-25
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 17,069,000 21,698,000 20,048,000 84,178,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 17,091,000 21,603,000 19,945,000 83,916,000
Diluted Earnings Per Share UNPUB UNPUB 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -14,539,000 -18,306,000 -17,632,000 -72,111,000
Income/Loss From Continuing Operations Before Tax -14,539,000 -18,306,000 -17,632,000 -72,111,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -14,539,000 -18,306,000 -17,632,000 -72,111,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -14,539,000 -18,306,000 -17,632,000 -72,111,000
Net Income/Loss Available To Common Stockholders, Basic -17,301,000 -18,306,000 -17,632,000 -74,873,000
Operating Expenses 17,091,000 21,603,000 19,945,000 83,916,000
Operating Income/Loss -14,561,000 -18,211,000 -17,529,000 -71,849,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 2,762,000
Preferred Stock Dividends And Other Adjustments 0 0 0 2,762,000
Revenues 2,530,000 3,392,000 2,416,000 12,067,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-08 2020-03-04
Assets 64,313,000 51,752,000 81,696,000 68,976,000
Current Assets 60,276,000 47,746,000 77,488,000 65,814,000
Current Liabilities 18,897,000 18,608,000 31,579,000 30,199,000
Equity 43,862,000 31,782,000 48,962,000 37,835,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 43,862,000 31,782,000 48,962,000 37,835,000
Liabilities 20,451,000 19,970,000 32,734,000 31,141,000
Liabilities And Equity 64,313,000 51,752,000 81,696,000 68,976,000
Noncurrent Assets 4,037,000 4,006,000 4,208,000 3,162,000
Noncurrent Liabilities 0 0 1,155,000 942,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-08 2020-03-04
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 -738,000 -14,294,000
Net Cash Flow, Continuing 0 0 -738,000 -14,294,000
Net Cash Flow From Financing Activities 17,155,000 12,834,000 -17,357,000 14,273,000
Net Cash Flow From Financing Activities, Continuing 17,155,000 12,834,000 -17,357,000 14,273,000
Net Cash Flow From Investing Activities -9,000 -26,000 0 -35,000
Net Cash Flow From Investing Activities, Continuing -9,000 -26,000 0 -35,000
Net Cash Flow From Operating Activities -17,146,000 -12,808,000 16,619,000 -28,532,000
Net Cash Flow From Operating Activities, Continuing -17,146,000 -12,808,000 16,619,000 -28,532,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-08 2020-03-04
Comprehensive Income/Loss -16,561,000 -13,547,000 2,595,000 -41,092,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,561,000 -13,547,000 3,039,000 -41,092,000
Other Comprehensive Income/Loss 0 0 0 -41,092,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-09 2019-08-08 2019-11-08 2020-03-04
Basic Earnings Per Share -1 0 0 -2
Benefits Costs and Expenses UNPUB UNPUB 16,061,000 62,007,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 16,072,000 62,639,000
Diluted Earnings Per Share -1 0 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,561,000 -13,547,000 2,595,000 -41,092,000
Income/Loss From Continuing Operations Before Tax -16,561,000 -13,547,000 2,595,000 -41,092,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,561,000 -13,547,000 2,595,000 -41,092,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,561,000 -13,547,000 3,039,000 -41,092,000
Net Income/Loss Available To Common Stockholders, Basic -16,561,000 -13,547,000 2,595,000 -41,092,000
Operating Expenses 16,404,000 14,268,000 16,072,000 62,639,000
Operating Income/Loss -16,404,000 -14,268,000 3,028,000 -41,724,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 444,000 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 19,100,000 20,915,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-10 2018-08-09 2018-11-08 2019-02-28
Assets 70,247,000 107,008,000 92,809,000 79,112,000
Current Assets 68,990,000 105,994,000 91,961,000 77,129,000
Current Liabilities 11,519,000 14,918,000 13,562,000 19,892,000
Equity 50,919,000 82,138,000 69,932,000 59,139,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 50,919,000 82,138,000 69,932,000 59,139,000
Liabilities 19,328,000 24,870,000 22,877,000 19,973,000
Liabilities And Equity 70,247,000 107,008,000 92,809,000 79,112,000
Noncurrent Assets 1,257,000 1,014,000 848,000 1,983,000
Noncurrent Liabilities 7,809,000 9,952,000 9,315,000 81,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-10 2018-08-09 2018-11-08 2019-02-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -7,803,000 35,944,000 -5,174,000 13,749,000
Net Cash Flow, Continuing -7,803,000 35,944,000 -5,174,000 13,749,000
Net Cash Flow From Financing Activities 6,468,000 51,775,000 -2,078,000 56,153,000
Net Cash Flow From Financing Activities, Continuing 6,468,000 51,775,000 -2,078,000 56,153,000
Net Cash Flow From Investing Activities 451,000 -298,000 9,688,000 14,301,000
Net Cash Flow From Investing Activities, Continuing 451,000 -298,000 9,688,000 14,301,000
Net Cash Flow From Operating Activities -14,722,000 -15,533,000 -12,784,000 -56,705,000
Net Cash Flow From Operating Activities, Continuing -14,722,000 -15,533,000 -12,784,000 -56,705,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-10 2018-08-09 2018-11-08 2019-02-28
Comprehensive Income/Loss -16,749,000 -16,306,000 -13,619,000 -59,008,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -16,759,000 -16,291,000 -13,617,000 -59,008,000
Other Comprehensive Income/Loss 0 0 0 -59,008,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2018-05-10 2018-08-09 2018-11-08 2019-02-28
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,749,000 -16,306,000 -13,619,000 -59,016,000
Income/Loss From Continuing Operations Before Tax -16,749,000 -16,306,000 -13,619,000 -59,016,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,749,000 -16,306,000 -13,619,000 -59,016,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,749,000 -16,306,000 -13,619,000 -59,016,000
Net Income/Loss Available To Common Stockholders, Basic -16,749,000 -26,635,000 -13,619,000 -69,345,000
Operating Expenses 16,810,000 15,152,000 14,725,000 63,285,000
Operating Income/Loss -16,810,000 -15,152,000 -14,725,000 -63,285,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 10,329,000
Preferred Stock Dividends And Other Adjustments 0 0 0 10,329,000
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-10 2017-08-09 2017-11-08 2018-02-27
Assets 92,763,000 81,158,000 67,436,000 79,035,000
Current Assets 91,281,000 79,803,000 66,203,000 77,670,000
Current Liabilities 6,886,000 10,658,000 8,617,000 12,085,000
Equity 75,989,000 61,264,000 50,573,000 59,744,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 75,989,000 61,264,000 50,573,000 59,744,000
Liabilities 16,774,000 19,894,000 16,863,000 19,291,000
Liabilities And Equity 92,763,000 81,158,000 67,436,000 79,035,000
Noncurrent Assets 1,482,000 1,355,000 1,233,000 1,365,000
Noncurrent Liabilities 9,888,000 9,236,000 8,246,000 7,206,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-10 2017-08-09 2017-11-08 2018-02-27
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -3,169,000 -4,186,000 -23,736,000 -24,554,000
Net Cash Flow, Continuing -3,169,000 -4,186,000 -23,736,000 -24,554,000
Net Cash Flow From Financing Activities 65,000 5,000 3,000 20,884,000
Net Cash Flow From Financing Activities, Continuing 65,000 5,000 3,000 20,884,000
Net Cash Flow From Investing Activities 11,284,000 7,841,000 -9,871,000 4,471,000
Net Cash Flow From Investing Activities, Continuing 11,284,000 7,841,000 -9,871,000 4,471,000
Net Cash Flow From Operating Activities -14,518,000 -12,032,000 -13,868,000 -49,909,000
Net Cash Flow From Operating Activities, Continuing -14,518,000 -12,032,000 -13,868,000 -49,909,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-10 2017-08-09 2017-11-08 2018-02-27
Comprehensive Income/Loss -13,398,000 -16,645,000 -12,257,000 -55,735,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -13,401,000 -16,641,000 -12,258,000 -55,735,000
Other Comprehensive Income/Loss 0 0 0 -55,735,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2017-05-10 2017-08-09 2017-11-08 2018-02-27
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -13,398,000 -16,645,000 -12,257,000 -55,728,000
Income/Loss From Continuing Operations Before Tax -13,398,000 -16,645,000 -12,257,000 -55,728,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -13,398,000 -16,645,000 -12,257,000 -55,728,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -13,398,000 -16,645,000 -12,257,000 -55,728,000
Net Income/Loss Available To Common Stockholders, Basic -13,398,000 -16,645,000 -12,257,000 -55,728,000
Operating Expenses 13,398,000 16,615,000 12,249,000 55,721,000
Operating Income/Loss -13,398,000 -16,615,000 -12,249,000 -55,721,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-12 2016-08-11 2016-11-10 2017-03-15
Assets 99,223,000 90,024,000 82,232,000 106,962,000
Current Assets 97,517,000 88,231,000 80,579,000 105,398,000
Current Liabilities 4,056,000 5,125,000 8,232,000 8,909,000
Equity 95,078,000 84,809,000 73,915,000 88,179,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 95,078,000 84,809,000 73,915,000 88,179,000
Liabilities 4,145,000 5,215,000 8,317,000 18,783,000
Liabilities And Equity 99,223,000 90,024,000 82,232,000 106,962,000
Noncurrent Assets 1,706,000 1,793,000 1,653,000 1,564,000
Noncurrent Liabilities 89,000 90,000 85,000 9,874,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-12 2016-08-11 2016-11-10 2017-03-15
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -10,858,000 -22,433,000 -4,649,000 22,805,000
Net Cash Flow, Continuing -10,858,000 -22,433,000 -4,649,000 22,805,000
Net Cash Flow From Financing Activities 41,000 25,000 -57,000 37,094,000
Net Cash Flow From Financing Activities, Continuing 41,000 25,000 -57,000 37,094,000
Net Cash Flow From Investing Activities -13,000 -12,986,000 3,095,000 25,482,000
Net Cash Flow From Investing Activities, Continuing -13,000 -12,986,000 3,095,000 25,482,000
Net Cash Flow From Operating Activities -10,886,000 -9,472,000 -7,687,000 -39,771,000
Net Cash Flow From Operating Activities, Continuing -10,886,000 -9,472,000 -7,687,000 -39,771,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-12 2016-08-11 2016-11-10 2017-03-15
Comprehensive Income/Loss -9,789,000 -11,755,000 -12,227,000 -48,158,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -9,783,000 -11,757,000 -12,240,000 -48,158,000
Other Comprehensive Income/Loss 0 0 0 -48,158,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2016-05-12 2016-08-11 2016-11-10 2017-03-15
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -9,789,000 -11,755,000 -12,227,000 -48,165,000
Income/Loss From Continuing Operations Before Tax -9,789,000 -11,755,000 -12,227,000 -48,165,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -9,789,000 -11,755,000 -12,227,000 -48,165,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -9,789,000 -11,755,000 -12,227,000 -48,165,000
Net Income/Loss Available To Common Stockholders, Basic -9,789,000 -11,755,000 -12,227,000 -48,165,000
Operating Expenses 9,885,000 11,862,000 12,336,000 48,436,000
Operating Income/Loss -9,885,000 -11,862,000 -12,336,000 -48,436,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2015-08-11 2015-11-16 2016-03-18
Assets UNPUB 123,953,000 116,988,000 109,974,000
Current Assets UNPUB 123,050,000 115,365,000 108,218,000
Current Liabilities UNPUB 3,068,000 4,275,000 5,974,000
Equity UNPUB 120,857,000 112,625,000 103,912,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 120,857,000 112,625,000 103,912,000
Liabilities UNPUB 3,096,000 4,363,000 6,062,000
Liabilities And Equity UNPUB 123,953,000 116,988,000 109,974,000
Noncurrent Assets UNPUB 903,000 1,623,000 1,756,000
Noncurrent Liabilities UNPUB 28,000 88,000 88,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2015-08-11 2015-11-16 2016-03-18
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB 64,177,000 -57,830,000 39,766,000
Net Cash Flow, Continuing UNPUB 64,177,000 -57,830,000 39,766,000
Net Cash Flow From Financing Activities UNPUB 70,169,000 -38,000 111,813,000
Net Cash Flow From Financing Activities, Continuing UNPUB 70,169,000 -38,000 111,813,000
Net Cash Flow From Investing Activities UNPUB -126,000 -50,489,000 -46,088,000
Net Cash Flow From Investing Activities, Continuing UNPUB -126,000 -50,489,000 -46,088,000
Net Cash Flow From Operating Activities UNPUB -5,866,000 -7,303,000 -25,959,000
Net Cash Flow From Operating Activities, Continuing UNPUB -5,866,000 -7,303,000 -25,959,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2015-08-11 2015-11-16 2016-03-18
Comprehensive Income/Loss UNPUB -6,414,000 -9,174,000 -32,201,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -6,414,000 -9,179,000 -32,201,000
Other Comprehensive Income/Loss UNPUB 0 0 -32,201,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2015-08-11 2015-11-16 2016-03-18
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -6,414,000 -9,174,000 -32,193,000
Income/Loss From Continuing Operations Before Tax UNPUB -6,414,000 -9,174,000 -32,193,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -6,414,000 -9,174,000 -32,193,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -6,414,000 -9,174,000 -32,193,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -6,414,000 -9,174,000 -32,193,000
Operating Expenses UNPUB 6,446,000 9,207,000 32,313,000
Operating Income/Loss UNPUB -6,446,000 -9,207,000 -32,313,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 0 0 0
Calendar
3 May 2024 (Time UTC) Actual Previous Consensus
★
19:45
United States
★★
19:45
United States
★
15:30
United States
-24500.000
-43400.000
★
15:30
United States
-162300.000
-154600.000
★
15:30
United States
54500.000
59300.000
★
15:30
United States
-150200.000
-132500.000
★★
15:30
United States
2800.000
6100.000
★
15:30
United States
-143400.000
-160200.000
★
15:30
United States
58100.000
58400.000
★
15:30
United States
1400.000
1300.000
★
15:30
United States
265500.000
264800.000
★
15:30
United States
43100.000
67700.000
★
15:30
United States
204200.000
202900.000
★★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:CDTX240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:CDTX240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:CDTX240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:CDTX240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:CDTX240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:CDTX240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:CDTX240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:CDTX240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:CDTX240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:CDTX240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:CDTX240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:CDTX240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:CDTX240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:CDTX240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:CDTX240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:CDTX240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:CDTX240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:CDTX240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:CDTX240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:CDTX240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:CDTX240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:CDTX240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:CDTX240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:CDTX240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:CDTX231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:CDTX231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:CDTX231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:CDTX231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:CDTX231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:CDTX231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:CDTX231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:CDTX231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:CDTX231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:CDTX231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:CDTX231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:CDTX231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:CDTX231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:CDTX231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:CDTX231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:CDTX231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:CDTX231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:CDTX231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:CDTX230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:CDTX230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:CDTX230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:CDTX230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:CDTX230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:CDTX230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:CDTX230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:CDTX230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:CDTX230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:CDTX230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:CDTX230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:CDTX230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held April 27-30, 2024 in Barcelona, Spain.
GlobeNewswire Inc. • 1w ago
Stocks Financing Agreements
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin. Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan. Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations. Cidara estimates that it will achieve approximately $128 million in cost savings over the patent life of rezafungin comprised of approximately $67 million in clinical development expense, including the cost of the potential upsizing of the ReSPECT trial and CMC costs over the next three years, and an additional approximately $61 million in forecasted obligations through the expected patent life of rezafungin.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline.
GlobeNewswire Inc. • 1w ago
Stocks Stock Market News
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study
GlobeNewswire Inc. • 4w ago
Health Health
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.
GlobeNewswire Inc. • 3mo ago
Health Health
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.
GlobeNewswire Inc. • 4mo ago
News Product / Services Announcement
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis.
GlobeNewswire Inc. • 4mo ago
Health Health
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA.
GlobeNewswire Inc. • 6mo ago
Stocks Earnings Releases and Operating Results
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an update on its corporate activities and product pipeline.
GlobeNewswire Inc. • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT